See every side of every news story
Published loading...Updated

Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice

  • The US Food and Drug Administration has determined that semaglutide is no longer in shortage, impacting patients who use compounded versions of the medication.
  • The US Food and Drug Administration has removed semaglutide from its shortage list, allowing Novo Nordisk's Ozempic and Wegovy to be widely available for patients.
  • Novo Nordisk can now meet the current and future demand in the US for its diabetes and weight-loss medications, ending a two-year shortage.
Insights by Ground AI
Does this summary seem wrong?

47 Articles

All
Left
8
Center
18
Right
5
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 58% of the sources are Center
58% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Science Alert broke the news in Australia on Friday, February 21, 2025.
Sources are mostly out of (0)